During a visit to the Russky Innovative Science and Technology Center, resident companies introduced Yury Trutnev to a range of projects in biomedicine and pharmaceuticals. The Deputy Prime Minister and Presidential Plenipotentiary Envoy to the Far Eastern Federal District toured the facilities, where he was briefed on several key initiatives.

The tour highlighted a project to develop Russian analogues of drugs for treating socially significant diseases, representing a total investment of 1 billion rubles.

The official also reviewed plans for the production of Russia’s first targeted anticoagulant, Dimolegin. The drug is designed to block two key blood clotting factors simultaneously.

The discussions covered next-generation test systems and glucometers, which promise not only high-precision measurements but also a 20% lower cost than imported alternatives.

Further projects aimed at reducing Russia’s import dependency for pharmaceutical substances and cosmetics were also outlined.

“The technological development of the Far East must be strengthened,” Trutnev stated. “The world is transitioning to a new paradigm – a pivotal shift that is fundamentally transforming the global landscape. We cannot afford to remain on the sidelines.”